SQZ fast tracked for HPV16+ Tumor therapy

 

• Designation Represents Potential to Bring Important New Therapy to Patients Earlier

• Stable Disease Observed in Two Out of Four Evaluable Patients in eAPC Phase 1/2 Trial Including a Pronounced Pharmacodynamic Response in a Patient with Prolonged Stable Disease

• Interim Results from Ongoing SQZ® eAPC Phase 1/2 Trial Showed Favorable Safety Data and Investigational Therapy was Generally Well Tolerated

• Median Drug Viability of Greater than 90 Percent for Both SQZ® eAPC and SQZ® APC Clinical Trials

https://finance.yahoo.com/news/sqz-biotechnologies-receives-fda-fast-114500828.html